Abstract
Current knowledge of the genetic heterogeneity of the most aggressive molecular subtype of breast cancer (BC) - triple negative (TN) - has led to promising discoveries in drug treatment, including the use of DNA-damaging agents (platinum drugs and PARP inhibitors) in these tumors, as well as current use of immunotherapy.
 Of greatest importance is the ability to prescribe optimal drug treatment regimens to patients with TN in breast cancer, based on knowledge of the molecular genetic characteristics of this subtype of breast cancer, which will ultimately allow achieving high rates of overall and relapse-free survival. Thus, the identification of the molecular genetic phenotype of breast carcinomas is an important prognostic factor of the disease and makes it possible to personalize the treatment of patients.
 The purpose of this work was to present a new approach to the molecular genetic classification of TN in breast cancer with predicting the outcome of patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
